ACELYRIN Inc (SLRN) Actualités

Form 8-K - Current report

ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease

Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate...

ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab

LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma...

Form 8-K - Current report

ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis

Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve...

Form S-3 - Registration statement under Securities Act of 1933

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights

Topline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024

LOS ANGELES, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma...

Form 8-K/A - Current report: [Amend]

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease

Experts and advocates to provide important strategic input and clinical expertise as ACELYRIN completes its...

ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024

LOS ANGELES, Sept. 19, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical...